XBIState Street SPDR S&P Biotech ETF

Grow my money20y track recordRanked #154 of 2,960 in this goal

Seeks to provide investment results that correspond generally to the total return performance of an index derived from the biotechnology segment.

By State Street Investment Management · Launched 2006

Annual Cost

0.35%

#1,706 of 5,562 · low cost

Fund Size

$8.4B

#307 of 5,562 · large

Return (1Y)Goal

+67.8%

Track Record

20 years

#266 of 5,562 · established

Performance

Total-return NAV · USD

Growth of $10,000

$17,303+73.0%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Index tracking

Sector

Health care

Focus

Biotech & Genomics

Index tracked

S&P Biotechnology Select Industry Index

What it actually holds

By weight

Concentration

Top 10 holdings = 21.9% of fund✓ well diversified

State Street Global Advisors

9.7%

Amicus Therapeutics Inc

1.5%

Praxis Precision Medicines Inc

1.4%

Travere Therapeutics Inc

1.4%

BioMarin Pharmaceutical Inc

1.4%

Halozyme Therapeutics Inc

1.3%

Roivant Sciences Ltd

1.3%

Exelixis Inc

1.3%

Regeneron Pharmaceuticals Inc

1.3%

Vaxcyte Inc

1.3%

Asset allocation

Stocks

100.0%

Cash

0.0%

By sector

Healthcare

99.7%

Financial Services

0.3%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

26.3%High

Year-on-year price swings

Max drawdown

-63.9%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.56Decent risk-adjusted returns

Sortino (3Y)

0.82Moderate downside risk

Where to buy

Listing

Exchange: NYSE Arca

Full fund details

Objective: Seeks to provide investment results that correspond generally to the total return performance of an index derived from the biotechnology segment.
Strategy: Employs a sampling strategy to track the S&P Biotechnology Select Industry Index, investing at least 80% of total assets in securities of the Index. The Fund may invest in a subset of the Index securities to match its risk and return characteristics.
Inception date: January 31, 2006
Fund family: State Street Investment Management